MARLTON REHAB HOSPITAL
1. Target Overview & Investment Thesis
MARLTON REHAB HOSPITAL is a 61-bed suburban community hospital in BURLINGTON, NJ with $38.4M in net patient revenue and a 9.5% operating margin. The hospital serves a payer mix of 41.6% Medicare, 2.6% Medicaid, and 55.8% commercial.
Thesis: Turnaround. Our ML models identify $2.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 9.5% to 16.8% (+736bps).
| Net Revenue HCRIS | $38.4M |
| Current EBITDA COMPUTED | $3.6M |
| Operating Margin COMPUTED | 9.5% |
| Occupancy HCRIS | 93.0% |
| Revenue / Bed COMPUTED | $629K |
| Net-to-Gross HCRIS | 36.7% |
| Distress Probability ML | 40.0% |
2. Market Context & Competitive Position
NJ has 95 Medicare-certified hospitals with a median operating margin of -3.9%. The target's margin of 9.5% places it above the state median. Among 29 size-comparable peers (30-122 beds), the median margin is -3.8%. The target performs in line with or above peers.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (30-122), prioritizing same-state peers. 29 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| MARLTON REHAB HOSPITAL (Target) | NJ | 61 | $38.4M | 9.5% |
| DEBORAH HEART AND LUNG CENTER | NJ | 85 | $211.9M | -5.5% |
| ST LUKES WARREN HOSPITAL | NJ | 92 | $200.8M | 28.1% |
| BERGEN NEW BRIDGE MEDICAL CENT | NJ | 101 | $187.0M | -39.4% |
| ST. MARYS HOSPITAL - PASSAIC | NJ | 122 | $173.8M | 0.9% |
| HUDSON REGIONAL HOSPITAL | NJ | 102 | $152.7M | 2.4% |
| CHILDRENS SPECIALIZED HOPSITAL | NJ | 68 | $150.1M | -18.1% |
| HACKENSACK UMC AT PASCACK VALL | NJ | 78 | $148.8M | 15.0% |
| HOBOKEN UNIVERSITY MEDICAL CEN | NJ | 114 | $133.9M | -48.9% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.8M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $806K | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $767K | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $760K | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $467K | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $25K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $3.6M |
| + RCM Uplift | +$2.8M |
| Pro Forma EBITDA | $6.5M |
| Current Margin | 9.5% |
| Pro Forma Margin | 16.8% |
| WC Released (1x) | $1.5M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $5.6M | $52.2M | 9.34x | 56.4% |
| Base (11x exit) | 10.0x | 11.0x | $5.6M | $59.2M | 10.60x | 60.4% |
| Bull Case | 9.0x | 11.0x | $5.0M | $70.3M | 13.99x | 69.5% |
| Bull (12x exit) | 9.0x | 12.0x | $5.0M | $78.2M | 15.56x | 73.2% |
| Bear Case | 11.0x | 10.0x | $6.1M | $36.3M | 5.90x | 42.6% |
| Bear (11x exit) | 11.0x | 11.0x | $6.1M | $41.9M | 6.82x | 46.8% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| Medium | Standard execution risk | RCM improvement requires management buy-in and 12-18 month implementation timeline |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 29 hospitals with 30-122 beds
- Same-state prioritization (n=30)
- Comp margins: P25=-27.1% / P50=-3.8% / P75=2.8%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.